 | Up a level |
Journal Article
Einsele, H., Vogel, M., Mueller, J., Knop, S., Kropff, M., Langer, C., Sayer, H., Jung, W., Wandt, H., Bassermann, F., Gramatzki, M., Roesler, W., Brugger, W., Engelhardt, M., Fischer, T., Giagounidis, A., Heidemann, E., Kroeger, N., Sezer, O., Bentz, M., Pfreundschuh, M., Salwender, H., Ludwig, W. -D., Roellig, C., Staib, P., Runde, V., Scheid, C., Ostermann, H., Hess, G., Hebart, H., Repp, R., Hart, C., Frickhofen, N., Straka, C. and Pflueger, K. -H. (2015). RESULTS FROM TWO PHASE 3 STUDIES OF POST-TRANSPLANT BORTEZOMIB (BTZ) CONSOLIDATION VS OBSERVATION (OBS) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM). Haematologica, 100. S. 151 - 152. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Fritsch, K., Kasenda, B., Schorb, E., Hau, P., Bloehdorn, J., Moehle, R., Loew, S., Binder, M., Atta, J., Keller, U., Wolf, H-H, Krause, S. W., Hess, G., Naumann, R., Sasse, S., Hirt, C., Lamprecht, M., Martens, U., Morgner, A., Panse, J., Frickhofen, N., Roeth, A., Hader, C., Deckert, M., Fricker, H., Ihorst, G., Finke, J. and Illerhaus, G. (2017). High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia, 31 (4). S. 846 - 853. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Haas, M., Waldschmidt, D., Stahl, M., Reinacher-Schick, A., Freiberg-Richter, J., Kaiser, F., Kanzler, S., Frickhofen, N., Seufferlein, T., Dechow, T., Mahlberg, R. J. C., Malfertheiner, P., Illerhaus, G., Kubicka, S., Held, S., Westphalen, C. B., Kruger, S., Boeck, S. and Heinemann, V. (2018). Gemcitabine plus afatinib versus gemcitabine alone in metastatic pancreatic cancer: An explorative randomized AIO phase II trial (ACCEPT). Ann. Oncol., 29. S. 243 - 244. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Haas, M., Waldschmidt, D. T., Stahl, M., Reinacher-Schick, A., Freiberg-Richter, J., von Weikersthal, L. Fischer, Kaiser, F., Kanzler, S., Frickhofen, N., Seufferlein, T., Dechow, T., Mahlberg, R., Malfertheiner, P., Illerhaus, G., Kubicka, S., Abdul-Ahad, A., Snijder, R., Kruger, S., Westphalen, C. B., Held, S., Von Bergwelt-Baildon, M., Boeck, S. and Heinemann, V (2021). Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method. Eur. J. Cancer, 146. S. 95 - 107. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Spiess, B., Reinwald, M., Postina, P., Cornely, O. A., Heussel, C. -P, Heinz, W., Lehrnbecher, T., Bertz, H., Hahn, J., Janssen, G., Claus, B., Lauten, M., Egerer, G., Behrends, U., Nathrath, M., Wolf, H. -H, Gruhn, B., Frickhofen, N., Woessmann, W., Will, S., Merker, N., Boch, T., Hofmann, W. -K and Buchheidt, D. (2014). Detection of fungal DNA in Aspergillus PCR-negative tissue biopsy samples from immunocompromised hematological patients using DNA microarray technology improves diagnosis of invasive fungal infections (IFI). Oncol. Res. Treat., 37. S. 93 - 94. BASEL: KARGER. ISSN 2296-5262
Thurner, L., Held, G., Poeschel, V, Berdel, C., Ott, G., Schmidt, C., Viardot, A., Engel-Riedel, W., Borchmann, P., Shpilberg, O., Witzens-Harig, M., Frickhofen, N., Nickelsen, M., Griesinger, F., Krammer-Steiner, B., Neubauer, A., Federico, M., Brown, de Nully P., Stilgenbauer, S., Murawski, N., Altmann, B., Truemper, L., Schmidberger, H., Ruebe, C., Fleckenstein, J., Schmitz, N., Loeffler, M. and Ziepert, M. (2020). Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: a subgroup analysis of the unfolder trial of the German Lymphoma Alliance (GLA). Oncol. Res. Treat., 43 (SUPPL 4). S. 61 - 62. BASEL: KARGER. ISSN 2296-5262
Tschanter, P., Krug, U., Fueller, M., Klein, M., Goellner, S., Rohde, C., Roellig, C., Thiede, C., Lilly, M. A., Haack, B., Koschmieder, A., Stelljes, M., Dugas, M., Koschmieder, S., Gerss, J., Butterfass-Bahloul, T., Wagner, R., Eveslage, M., Thiem, U., Krause, S. W., Kaiser, U., Kunzmann, V, Steffen, B., Noppeney, R., Herr, W., Baldus, C. D., Schmitz, N., Goetze, K., Reichle, A., Kaufmann, M., Neubauer, A., Schaefer-Eckart, K., Haenel, M., Peceny, R., Frickhofen, N., Kiehl, M., Giagounidis, A., Goerner, M., Repp, R., Link, H., Kiani, A., Naumann, R., Bruemmendorf, T. H., Serve, H., Ehninger, G., Berdel, W. E. and Mueller-Tidow, C. (2015). DNMT3A mutations in exon 23 are associated with improved survival in AML patients treated with Azacytidine plus standard chemotherapy. Oncol. Res. Treat., 38. S. 122 - 123. BASEL: KARGER. ISSN 2296-5262